Trial Profile
A 24-month, muti-center, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled everolimus with reduced cyclosporine versus 3.0g mycophenolate mofetil with standard dose cyclosporine in de novo heart transplant recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Steroids
- Indications Heart transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
- 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
- 09 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.